Treatment of infections caused by microorganisms sensitive to cefuroxime, or treatment of infections prior to determining the pathogen.
Composition and form of release
Zinacef is made up into a powder for solution for injection. The main active ingredient is cefuroxime.
Zinacef is used in the treatment of infectious and inflammatory diseases caused by bacteria susceptible to cefuroxime. The drug is used in therapy:
- bronchitis, pneumonia, infected bronchiectasis, lung abscess, infectious diseases of the chest, arising after surgery;
- sore throat, otitis media, sinusitis, pharyngitis;
- erysipelas, boils, infected wounds;
- cystitis, pyelonephritis, asymptomatic bacteriuria, gonorrhea;
- osteomyelitis, septic arthritis;
- infectious lesions of the pelvic organs;
In addition, Zinacef is used to prevent infectious complications during operations on the abdominal and pelvic organs, as well as the heart, esophagus, lungs, blood vessels, bones and joints.
Zinacef is not prescribed to patients with established intolerance to penicillins and cephalosporins, as well as with a tendency to bleeding and various diseases of the gastrointestinal tract.
Use during pregnancy and breastfeeding
Due to the fact that it is unknown whether or not Zinacef has teratogenic or embryotoxic effects, its use is contraindicated in the first trimester of pregnancy. In later stages of pregnancy, as well as during lactation, the use of the drug is possible only for serious medical reasons.
Method of application and dose
Zinacef is intended for parenteral administration. Adult patients receive the drug every 8 hours at 750 mg. In the treatment of severe infections, the drug is administered intravenously 1.5 g every 8 hours. If necessary, the drug can be administered every 4 hours. The highest daily dose of Zinacef is 6 g.
In the treatment of most infections, the dosage of Zinacef from 750 to 1.5 g twice a day is considered effective. The child’s daily dose can vary from 30 to 100 mg per 1 kg of body weight of the child, divided into 3 or 4 doses.
In case of Zinacef overdose, patients experience motor arousal, manifested by tremor and convulsions. If symptoms of overdose occur, hemodialysis or peritoneal dialysis is performed to reduce the concentration of cefuroxime in the body.
Occasionally, patients taking Zinacef develop headaches, convulsions, dizziness, decreased visual acuity, nausea, diarrhea, epigastric pain, candidal vaginitis, and renal impairment, dizziness, decreased visual acuity, and hearing loss.
Conditions and terms of storage
Zinacef should be stored in a dark, dry place out of the reach of children. Duration of storage of drug at observance of all storage conditions – 2 years.